Metformin was first used to treat type 2 diabetes in the late 1950s and in 2022 remains the
first-choice drug used daily by approximately 150 million people. An accumulation of …

Glucose and fructose are closely related simple sugars, but fructose has been associated
more closely with metabolic disease. Until the 1960s, the major dietary source of fructose …

Previous meta-analyses have shown that the antidiabetic agent metformin is associated with
reduced cancer incidence and mortality. However, this effect has not been consistently …

Patients with diabetes mellitus are at increased risk of cancer development. Metformin is a
well-established, effective agent for the management of type 2 diabetes mellitus …

The prevalence of diabetes is dramatically increasing worldwide. The results of numerous
epidemiological studies indicate that diabetic population is not only at increased risk of …

In recent years, several studies have presented evidence suggesting a potential role for
metformin in anti-cancer therapy. Preclinical studies have demonstrated several anticancer …

An estimated 10–25% of lung cancers worldwide occur in never smokers, ie individuals
having smoked less than 100 cigarettes in their lifetime. Lung cancer in never smokers …

OBJECTIVE Time-related biases in observational studies of drug effects have been
described extensively in different therapeutic areas but less so in diabetes. Immortal time …

Laboratory research and pharmacoepidemiology are providing converging evidence that
the widely used antidiabetic drug metformin has antineoplastic activity, but there are …

Metformin is a standard clinical drug used to treat type 2 diabetes mellitus (T2DM) and
polycystic ovary syndrome. Recently, epidemiological studies and meta‑analyses have …